Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with ΔFosB

Neuroscience

Volumn 144, Issue 1, 2007, Pages 198-207

  Valastro, B ^a,b   Andersson, M ^c   Lindgren, H S ^a   Cenci, M A ^a  

^a LUND UNIVERSITY   (Sweden)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DOPA; dyskinesia; immediate early genes; Parkinson's disease; striatum; transcription factor AP1

Indexed keywords

LEVODOPA; MESSENGER RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR DELTA FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSKINESIA; FEMALE; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STABILITY; RAT; RECEPTOR UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIPARKINSON AGENTS; BLOTTING, WESTERN; DENERVATION; FEMALE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEVODOPA; NEOSTRIATUM; OXIDOPAMINE; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 33751571650     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.09.001     Document Type: Article

References (42)

1. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6 (1999) 461-474
2. Andersson M., Konradi C., and Cenci M.A. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21 (2001) 9930-9943
3. Andersson M., Westin J.E., and Cenci M.A. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci 17 (2003) 661-666
4. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., and Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18 (1998) 5301-5310
5. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2 (2001) 577-588
6. Calon F., Hadj Tahar A., Blanchet P.J., Morissette M., Grondin R., Goulet M., Doucet J.P., Robertson G.S., Nestler E., Di Paolo T., and Bedard P.J. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 23 (2000) S92-S100
7. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., and Cenci M.A. Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96 (2006) 1718-1727
8. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 (1998) 2694-2706
9. Cenci M.A., Tranberg A., Andersson M., and Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94 (1999) 515-527
10. Chen J., Kelz M.B., Hope B.T., Nakabeppu Y., and Nestler E.J. Chronic Fos-related antigens: stable variants of deltaFosB induced in brain by chronic treatments. J Neurosci 17 (1997) 4933-4941
11. Chen J., Nye H.E., Kelz M.B., Hiroi N., Nakabeppu Y., Hope B.T., and Nestler E.J. Regulation of delta FosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol Pharmacol 48 (1995) 880-889
12. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St-Jean M., Wigle N., Blanchet P., Grondin R., and Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8 (1996) 365-381
13. Gass P., Herdegen T., Bravo R., and Kiessling M. Spatiotemporal induction of immediate early genes in the rat brain after limbic seizures: effects of NMDA receptor antagonist MK-801. Eur J Neurosci 5 (1993) 933-943
14. Grande C., Zhu H., Martin A.B., Lee M., Ortiz O., Hiroi N., and Moratalla R. Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol Psychiatry 55 (2004) 457-463
15. Herdegen T., and Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 28 (1998) 370-490
16. Herdegen T., Kovary K., Leah J., and Bravo R. Specific temporal and spatial distribution of JUN, FOS, and KROX-24 proteins in spinal neurons following noxious transsynaptic stimulation. J Comp Neurol 313 (1991) 178-191
17. Hirai S.I., Ryseck R.P., Mechta F., Bravo R., and Yaniv M. Characterization of junD: a new member of the jun proto-oncogene family. EMBO J 8 (1989) 1433-1439
18. Hiroi N., Marek G.J., Brown J.R., Ye H., Saudou F., Vaidya V.A., Duman R.S., Greenberg M.E., and Nestler E.J. Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures. J Neurosci 18 (1998) 6952-6962
19. Hope B.T., Nye H.E., Kelz M.B., Self D.W., Iadarola M.J., Nakabeppu Y., Duman R.S., and Nestler E.J. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 13 (1994) 1235-1244
20. Kamme F., and Wieloch T. Induction of junD mRNA after transient forebrain ischemia in the rat. Effect of hypothermia. Brain Res Mol Brain Res 43 (1996) 51-56
21. 1 transition in mouse fibroblasts: In vitro and in vivo associations. Mol Cell Biol 11 (1991) 2451-2459
22. MacGibbon G.A., Lawlor P.A., Bravo R., and Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain Res 23 (1994) 21-32
23. Mandelzys A., Gruda M.A., Bravo R., and Morgan J.I. Absence of a persistently elevated 37 kDa fos-related antigen and AP-1-like DNA-binding activity in the brains of kainic acid-treated fosB null mice. J Neurosci 17 (1997) 5407-5415
24. McClung C.A., Ulery P.G., Perrotti L.I., Zachariou V., Berton O., and Nestler E.J. DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res 132 (2004) 146-154
25. Moratalla R., Vickers E.A., Robertson H.A., Cochran B.H., and Graybiel A.M. Coordinate expression of c-fos and jun B is induced in the rat striatum by cocaine. J Neurosci 13 (1993) 423-433
26. Musti A.M., Treier M., Peverali F.A., and Bohmann D. Differential regulation of c-Jun and JunD by ubiquitin-dependent protein degradation. Biol Chem 377 (1996) 619-624
27. Nakabeppu Y., and Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 64 (1991) 751-759
28. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40 (1990) 340-345
29. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci 23 (2000) S2-S7
30. Okazaki S., Ito T., Ui M., Watanabe T., Yoshimatsu K., and Iba H. Two proteins translated by alternative usage of initiation codons in mRNA encoding a JunD transcriptional regulator. Biochem Biophys Res Commun 250 (1998) 347-353
31. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59 (2006) 64-74
32. Perez-Otano I., Mandelzys A., and Morgan J.I. MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Res Mol Brain Res 53 (1998) 41-52
33. Ryder K., Lanahan A., Perez-Albuerne E., and Nathans D. Jun-D: a third member of the jun gene family. Proc Natl Acad Sci U S A 86 (1989) 1500-1503
34. Short J.D., and Pfarr C.M. Translational regulation of the JunD messenger RNA. J Biol Chem 277 (2002) 32697-32705
35. Svenningsson P., Strom A., Johansson B., and Fredholm B.B. Increased expression of c-jun, junB, AP-1, and preproenkephalin mRNA in rat striatum following a single injection of caffeine. J Neurosci 15 (1995) 3583-3593
36. Svenningsson P., Arts J., Gunne L., and Andren P.E. Acute and repeated treatment with l-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets. Brain Res 955 (2002) 8-15
37. Ulery P.G., Rudenko G., and Nestler E.J. Regulation of FosB stability by phosphorylation. J Neurosci 26 (2006) 5131-5142
38. Vallone D., Pellecchia M.T., Morelli M., Verde P., DiChiara G., and Barone P. Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. Brain Res Mol Brain Res 52 (1997) 307-317
39. Westin J.E., Andersson M., Lundblad M., and Cenci M.A. Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14 (2001) 1171-1176
40. Winkler C., Kirik D., Bjorklund A., and Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10 (2002) 165-186
41. Yamada T., Nakao S., Osada S., Imagawa M., and Nishihara T. Sequence analysis of the rat jun-D gene. Gene 153 (1995) 285-286
42. Zerial M., Toschi L., Ryseck R.P., Schuermann M., Muller R., and Bravo R. The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity. EMBO J 8 (1989) 805-813